YB new stock pitches (Tue, Mar 17)

Floor & Decor Holdings (FND), a specialty flooring retailer previously compared to Costco by Munger, has fallen 45% since initial coverage and 35% year-over-year, with 60% of analysts rating it Hold, 30% Buy, and 10% Sell. The company maintains an industry-leading 43% gross margin versus 33% industry average through vertical integration sourcing from 26+ countries (China <5%), with 50% of sales coming from sticky 'Pro' B2B contractor customers who demand volume discounts and inventory availability. Bears argue the business is commoditizing as the housing market has collapsed with Existing Home Sales falling to 3.9 million from a historical 5.5 million norm, causing operating margins to compress from a 12% historical average to 6%, comps to fall 4.8% in 2025, and management to guide for -2% to +1% comps in 2026 with only 20 new store openings planned (current: 270 stores) versus prior aggressive expansion toward 500 stores by 2030. The shift to cheaper DIY-friendly Luxury Vinyl Plank flooring over traditional wood, stone, and marble tiles that require professional installation threatens FND's moat, while average ticket declined 0.6% last quarter and wage inflation hits harder due to need for expert employees to serve Pro customers. The stock trades at 30x trailing PE, compressed from 40x, with bears arguing it should trade closer to the 20x industry average if moats erode, implying 30% further downside, while bulls believe Fed rate cuts (delayed by Iran-Israel geopolitical tensions) will eventually revive the housing market and that current conditions represent a cyclical dip rather than structural decline, with FND consolidating market share as smaller competitors like Lumber Liquidators and The Tile Shop bleed out. The author views FND as attractive at 30x PE, believing the concerns are tied to the cyclical dip in Existing Home Sales which will eventually recover, with the risk/reward favorable unless interest rates stay high forever and permanently commoditize the business.

Read the full article here. Read time: 6 min

Marex Group (MRX), a diversified global financial services firm providing liquidity and market access across energy, commodities, and financial markets through four segments—Clearing Services, Agency & Execution, Market Making, and Hedging & Investment Solutions—has delivered exceptional growth with adjusted PBT increasing from $61M in 2020 to $418M in 2025 at a 47% CAGR and 30% YoY growth in 2025. The company's Prime Services business within Agency & Execution has driven 160% YoY profit growth, expanding pretax margins from 13.4% to 30.5% and now contributing 43% of total profits at $280.4M, while Clearing remains the high-margin bedrock generating $261.5M at nearly 50% margins despite headwinds from falling interest rates reducing interest income. Marex trades at just 8.4x 2026 EPS estimates versus peer StoneX at 13x forward multiple, despite generating a superior 30% adjusted ROE compared to StoneX's 22.5%, with the discount attributed to small-cap status, emerging technical selling pressure from private equity exit (now in low double digits), and market underestimation of organic growth and capital deployment potential. The company has a competitive advantage stemming from infrastructure capabilities that smaller firms cannot replicate and positioning in mid-market client niches that large banks have exited due to regulatory capital constraints, with barriers to entry from technical complexity, regulatory requirements, and capital needs. Key catalysts include the ending of PE exit pressure removing a major weight on shares, consistent market share gains in Clearing and Prime Services, cross-selling traction across the platform, supportive market making conditions with CME and ICE volumes remaining healthy and Bloomberg Commodity Index volatility elevated 15% quarter-over-quarter supporting spreads, margin expansion as the business scales with net income margins projected to reach 15.1% in 2026 from 11.1% in 2023, EPS growth from $3.99 in 2025 to nearly $5.00 in 2027, and strong insider buying from CEO and CFO signaling management confidence. The bull case centers on market mispricing, rapid revenue growth of 38% YoY in Q4 2025, proven M&A strategy with successful Prime Services integration from TD Cowen acquisition, potential re-rating from current 8.65x P/E and 2.17x P/B (well below 2024 average of 3.24x P/B) toward a 12x forward multiple, and analyst consensus of 86% Buy/Overweight ratings with average price target of $55.20 implying 53.5% upside. Key risks include cyclical volatility as the business is market-sensitive with mixed current conditions despite strong volumes, cost pressures with $15M-$20M quarterly expenses from recent Winterflood acquisition limiting margin expansion, elevated variable compensation comprising 55% of cost base, further interest rate cuts creating headwinds to clearing profitability and interest income, counterparty/credit/liquidity risks inherent to financial firms that take risk, potential for reduced client activity and trading volumes during prolonged bear markets, and exposure to commodity volumes particularly in energy and agriculture which could be depressed by geopolitical events like Strait of Hormuz closure. Aurelion Research and Welfare Capital Research model a price target of $51.84 representing 48% upside over the next twelve months, and the firm is adding MRX to the Aurelion Index as a new position based on the compelling risk/reward at current trough valuations just as private equity selling pressure ends and a new growth phase begins.

Read the full article here. Read time: 17 min

Rocket Doctor AI (AIRDF), a new position and the author's second highest conviction holding, is a digital health platform and marketplace trading at a $42 million market cap with 89% margins and 15 million eligible US patients. The company enables physicians to set up virtual practices, set their own hours, and see patients on their own terms with no middlemen, while major US insurers are rapidly approving the platform. Beyond the telemedicine marketplace, Rocket Doctor built the Global Library of Medicine (GLM) over nearly a decade before ChatGPT existed—a specialized medical AI system designed specifically for clinical workflows that provides real-time clinical decision support, higher diagnostic accuracy, reduced physician cognitive load, standardized evidence-based care, and better documentation and coding. Misdiagnosis costs the US healthcare system over $100 billion annually in excess costs, which the GLM directly addresses, and healthcare represents approximately 18% of America's GDP. Unlike general-purpose AI applied to medicine, the GLM was built from the ground up for physicians in private practice and specialist settings. The company combines healthcare AI, a live physician marketplace, a decade of specialized development, and 15 million eligible US patients at a $42 million valuation that the author believes significantly undervalues the opportunity if even a fraction of the potential is realized.

Read the full article here. Read time: 2 min